Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries
Abstract Background Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. With the introduction of new treatment classes, it is important to examine patient...
Main Authors: | Alison Davie, Gebra Cuyun Carter, Alex Rider, James Pike, Katie Lewis, Abigail Bailey, Gregory L. Price, Francois Ringeisen, Xavier Pivot |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-07294-2 |
Similar Items
-
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
by: Alison Davie, et al.
Published: (2023-09-01) -
Real-world study on HR+, HER2−, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns
by: X. Pivot, et al.
Published: (2021-04-01) -
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
by: Lu-Qi Cao, et al.
Published: (2024-01-01) -
An Evaluation of the Five Most Used Evidence Based Bedside Information Tools in Canadian Health Libraries
by: Alison Farrell
Published: (2008-06-01) -
Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients
by: Yuehua Liang, et al.
Published: (2024-01-01)